Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leavitt Backs Market Approach For Medicare Rx

This article was originally published in The Pink Sheet Daily

Executive Summary

HHS Secretary nominee Michael Leavitt affirmed his commitment to free market principles in the Medicare drug benefit while appearing before a Senate committee Jan. 18

You may also be interested in...



State Of The Union Health Care Agenda Leaves Out Medicare, Medicaid

President Bush calls for improved information technology and expanded health savings accounts in speech focused mostly on Social Security and foreign affairs. Bush's call for fiscal discipline could be the strongest signal concerning the Administration's plans for the implementation of the Medicare program next year.

State Of The Union Health Care Agenda Leaves Out Medicare, Medicaid

President Bush calls for improved information technology and expanded health savings accounts in speech focused mostly on Social Security and foreign affairs. Bush's call for fiscal discipline could be the strongest signal concerning the Administration's plans for the implementation of the Medicare program next year.

Medicare Rx Benefit Cost To Be Re-Estimated In President’s ’06 Budget

The final regulations will “keep drug prices down” but provide “more use of drugs,” CMS Administrator McClellan says. The Centers for Medicare & Medicaid Services is "on track" to deliver the prescription drug benefit on schedule, he says.

Related Content

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel